^
    Back
    Association details:
    Biomarker:FLT3-ITD mutation + NRAS mutation + GATA2 mutation
    Cancer:Acute Myelogenous Leukemia
    Drug:Venclexta (venetoclax) (Bcl2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    ASH 2021
    Title:

    Enhanced p53 Activation By Dual Inhibition of MDM2 and XPO1 Disrupts MYC Transcriptional Program and Restores Sensitivity to BCL-2 Inhibition in Ven/HMA Resistant AML

    Published date:
    11/04/2021
    Excerpt:
    Next, we treated NSG mice injected with PDX AML cells with FLT3-ITD, GATA2 and NRAS mutations obtained from a patient who relapsed after ven/decitabine treatment.
    Secondary therapy:
    decitabine
    DOI:
    10.1182/blood-2021-149260
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    ASH 2019
    Title:

    Inhibition of Mcl-1 Enhances the Efficacy of Tyrosine Kinase Inhibition in FLT3 Mutated AML and Synergizes with Venetoclax Targeting AML Stem Cells

    Published date:
    11/06/2019
    Excerpt:
    The second PDX model...harbors FLT3-ITD, NRAS, and GATA2 mutations...The combination was highly effective in this model and greatly decreased circulating blasts (Fig. 1) and leukemia tissue infiltration, measured by flow cytometry and spleen size.
    DOI:
    10.1182/blood-2019-125725